BCRX•benzinga•
BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings
Summary
BioCryst's Orladeyo showed sustained HAE attack reductions in real-world data. The company expects positive EPS and cash flow in the second half of 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 24, 2025 by benzinga